Retevmo selpercatinib logo
  • House For Patients
    • Understanding RET
    • How Retevmo Works
    • Retevmo in NSCLC
      • About Metastatic NSCLC
      • Retevmo for Metastatic NSCLC
    • Retevmo in Thyroid Cancer
    • Taking Retevmo
    • Savings & Support
  • For Healthcare Providers
    • Efficacy
    • Safety & Tolerability
    • Dosing
    • Savings & Support
Ask Lilly

We're here to help.

Phone Call:
1-800-LillyRx
(1-800-545-5979)
Expand contact lilly
Learn more about Retevmo in NSCLC

What is metastatic non-small cell lung cancer (NSCLC)?

Lung cancer is a cancer that starts in your lungs. There are 2 main types of lung cancer: NSCLC and small cell lung cancer. About 85% of people with lung cancer have NSCLC. Lung cancer may spread to other parts of the body, including bones, adrenal glands, the brain, and the liver. People with lung cancer whose cancer cells have spread to these places likely have metastatic cancer.

Metastatic NSCLC can be driven by a gene in your body. One of those genes is RET.

Talk to your doctor to see if your cancer is RET-positive.

Retevmo is available for RET-positive metastatic NSCLC



RET=rearranged during transfection.

Retevmo may help by targeting what is driving your RET-positive metastatic NSCLC

Retevmo was studied in the largest clinical trial of people with RET-positive cancers. The trial included 330 people with metastatic NSCLC, and 144 had tumors that were eligible to be evaluated for shrinkage. The trial evaluated how many people responded to treatment, which means their tumors either shrank or disappeared completely, and how long the response lasted.

Retevmo may affect both healthy cells and tumor cells, which can result in side effects, some of which can be serious.

Retevmo was shown to shrink tumors in the majority of people with RET-positive metastatic NSCLC

85%


of the 39 people who had never received any cancer treatment had an objective response, meaning their tumors shrank by 30% or more

  • Median* length of response has not yet been reached, as the trial is ongoing
64%


of the 105 people who had prior cancer treatment† had an objective response

  • Responses lasted a median* of 17.5 months

*Median is the middle number in a range of numbers.

In the trial, Retevmo reduced the size of tumors in the brain in people with metastatic RET-positive NSCLC who had prior cancer treatments†

10 of the 11


people whose metastatic NSCLC had spread to their brain saw their brain tumors shrink by at least 30% or disappear completely

  • All 10 people saw a response of 6 months or longer

†Platinum-based chemotherapy; some had also received other therapies.


SELECT SAFETY INFORMATION

Common side effects
The most common side effects of RETEVMO include:

  • increased levels of liver enzymes
  • increased blood sugar levels
  • decrease in white blood cell count
  • decreased protein levels (albumin) in the blood
  • decreased levels of calcium in the blood
  • dry mouth
  • diarrhea
  • increased creatinine (kidney function test)
  • high blood pressure
  • tiredness
  • swelling of your arms, legs, hands, and feet (peripheral edema)
  • decrease in platelet count
  • increased cholesterol levels
  • rash
  • decreased levels of salt (sodium) in the blood
  • constipation

RETEVMO may affect fertility in females and males, which may affect your ability to have children. Talk to your doctor if this is a concern for you.
These are not all the possible side effects with RETEVMO.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Retevmo dosing


Learn how to take Retevmo.

What is RET?


Read more about what could be driving your cancer.

Important Facts About RETEVMO® (reh-TEHV-moh). It is also known as selpercatinib.

RETEVMO is a prescription medicine that is used to treat certain cancers caused by an abnormal gene, called RET, in:

  • adults with non-small cell lung cancer (NSCLC) that has spread.
  • adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread, who need a medicine that can be taken by mouth or injection.
  • adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread, who need a medicine that can be taken by mouth or injection, and who have received radioactive iodine and it did not work or is no longer working.

Your doctor will perform a test to make sure that RETEVMO is right for you.

It is not known if RETEVMO is safe and effective in children younger than 12 years of age.

Warnings

RETEVMO may cause serious side effects, including:

Liver problems: Liver problems (higher levels of liver enzymes) are common with RETEVMO and may sometimes be serious. Your doctor will do blood tests before and during treatment with RETEVMO to check for liver problems. Tell your doctor right away if you get any of the following symptoms of liver problems during treatment:

  • yellowing of your skin or the white part of your eyes (jaundice)
  • dark, “tea-colored” urine
  • sleepiness
  • bleeding or bruising
  • loss of appetite
  • nausea or vomiting
  • pain on the upper right side of your stomach area

If you develop liver problems while taking RETEVMO, your doctor may lower your dose, stop treatment for a while, or stop treatment permanently.

High blood pressure (hypertension): High blood pressure is common with RETEVMO. It may sometimes be serious. You should check your blood pressure regularly during treatment with RETEVMO. Tell your doctor if you get any of the following symptoms during treatment:

  • confusion
  • headaches
  • shortness of breath
  • dizziness
  • chest pain

Heart rhythm changes (QT prolongation) can happen. These may be serious. RETEVMO may cause very slow, very fast, or irregular heartbeats. Tell your doctor right away if you get any of the following symptoms during treatment:

  • loss of consciousness
  • fainting
  • dizziness
  • a change in the way your heart beats (heart palpitations)

Bleeding problems: RETEVMO can cause bleeding, which can be serious and may lead to death. Tell your doctor if you have any signs of bleeding during treatment, including:

  • vomiting blood or if your vomit looks like coffee-grounds
  • pink or brown urine
  • red or black stools that look like tar
  • coughing up blood or blood clots
  • unusual bleeding or bruising of your skin
  • menstrual bleeding that is heavier than normal
  • unusual vaginal bleeding
  • nose bleeds that happen often
  • drowsiness or difficulty being woken up
  • confusion
  • headache
  • change in speech

Allergic reactions: RETEVMO can cause a fever, rash, or pain in muscles or joints, especially in the first month of treatment. Tell your doctor if you get any of these symptoms. Your doctor may stop treatment for a while or lower your dose of RETEVMO.

Risk of wound healing problems: Wounds may not heal well during treatment with RETEVMO. Tell your doctor if you plan to have any surgery before or during treatment with RETEVMO.

  • You should stop taking RETEVMO at least 7 days before planned surgery.
  • Your doctor should tell you when you may start taking RETEVMO again after surgery.

Common side effects

The most common side effects of RETEVMO are:

  • higher levels of liver enzymes
  • higher blood sugar levels
  • lower white blood cell count
  • lower protein (albumin) levels in the blood
  • lower calcium levels in the blood
  • dry mouth
  • diarrhea
  • higher creatinine levels (this measures kidney function)
  • high blood pressure
  • tiredness
  • swelling of your arms, legs, hands, and feet (peripheral edema)
  • lower platelet count
  • higher cholesterol levels
  • rash
  • lower salt (sodium) levels in the blood
  • constipation

RETEVMO may affect the ability to have children for both females and males. Talk to your doctor if you want to have children and you are thinking about starting treatment with RETEVMO.

  • RETEVMO can harm your unborn baby. You should not become pregnant during treatment with RETEVMO.
  • If you are able to become pregnant:
    • Your doctor will do a pregnancy test before you start treatment with RETEVMO.
    • You should use effective birth control (contraception) during treatment and for at least 1 week after the final dose of RETEVMO. Talk to your doctor about birth control methods that may be right for you.
    • Tell your doctor right away if you become pregnant or think you might be pregnant during treatment with RETEVMO.
  • Males with partners who are able to become pregnant should use effective birth control during treatment with RETEVMO and for at least 1 week after the final dose of RETEVMO.

These are not all the possible side effects with RETEVMO. If you are concerned about side effects, talk to your doctor. Tell your doctor about any side effects you have. You can also report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using

Before taking RETEVMO, tell your doctor about all your medical conditions, including if you:

  • have liver problems
  • have high blood pressure
  • have heart problems, including a condition called QT prolongation
  • have bleeding problems
  • plan to have surgery. You should stop taking RETEVMO at least 7 days before your planned surgery.
  • are pregnant or plan to become pregnant. See section above for additional information.
  • are breastfeeding or plan to breastfeed. It is not known if RETEVMO passes into your breast milk. Do not breastfeed during treatment with RETEVMO and for 1 week after the last dose.

Also tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain other medicines may affect how RETEVMO works.

  • You should avoid taking certain medicines when also taking RETEVMO. These include:
    • St. John’s wort,
    • proton-pump inhibitors (PPIs) such as dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, and rabeprazole,
    • H2 blockers such as famotidine, nizatidine, and cimetidine,
    • antacids that contain aluminum, magnesium, calcium, simethicone, or buffered medicines.

If you cannot avoid taking PPIs, H2 blockers, or antacids, see the “How to take with certain other medicines” section below for more information. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How to take RETEVMO

  • Take RETEVMO exactly as your doctor tells you.
  • Your doctor may stop treatment or change your dose of RETEVMO if you have side effects. Do not change your dose or stop taking RETEVMO unless your doctor tells you.
  • Swallow RETEVMO capsules whole. Do not chew or crush the capsules.
  • RETEVMO is taken by mouth, usually 2 times a day with or without food.
  • RETEVMO doses should be taken 12 hours apart.
  • If you vomit after taking a dose of RETEVMO, do not take an extra dose. Take the next dose of RETEVMO at your scheduled time.
  • Do not take a missed dose of RETEVMO unless it is more than 6 hours until your next scheduled dose.
  • If you take too much RETEVMO, call your doctor or go to the nearest hospital emergency room right away.

How to take RETEVMO with certain other medicines

  • If you take a PPI (such as dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, or rabeprazole), take RETEVMO with food.
  • If you take an antacid that contains aluminum, magnesium, calcium, simethicone, or buffered medicines, take RETEVMO 2 hours before or 2 hours after taking the antacid.
  • If you take an H2 blocker (such as famotidine, nizatidine, or cimetidine), take RETEVMO 2 hours before or 10 hours after taking the H2 blocker.

Learn more

For more information, call 1-800-545-5979.

This summary provides basic information about RETEVMO. It does not include all information known about this medicine. Read the information that comes with your medicine each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other health care provider about RETEVMO and how to take it. Your doctor is the best person to help you decide if RETEVMO is right for you.

RETEVMO® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

SE CON BS 17NOV2020

Prescribing Information
Patient Prescribing Information
Terms of Use
Privacy Statement
Accessibility Statement
Sitemap
Need assistance?
Call 1-800-545-5979

This site is intended for US residents aged 18 or older.

Retevmo® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

PP-SE-US-0031 02/2021 ©Lilly USA, LLC 2021. All rights reserved.

Terms of Use Privacy Statement Accessibility Statement Sitemap
Lilly